7 June 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas. The project involves the use of our proprietary Virtual Tumour technology to help guide the Phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024.
Dr Peter Sargent, CEO, commented: "We at Physiomics are very excited about starting our first project with this exciting new client and we look forward to working with their team over the coming months and hopefully on further programmes in the future".
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
